Zhongshan Pharmaceutical's application for listing of the new Chinese medicine 1.1 "Renshu Jianwei Granules" has been accepted. According to public information, the drug is intended to treat diseases such as atrophic gastritis and precancerous lesions of gastric mucosa.
Atrophic gastritis is a disease in which the gastric pits become shallower due to the thinning of the gastric mucosa and the reduction or partial disappearance of intrinsic glands such as acid-secreting glands and mucous glands on the gastric mucosa. According to the degree of gland reduction, atrophic gastritis can be divided into mild, moderate and severe atrophy. Gastric mucosal carcinogenesis is a type of cancer caused by dysplasia of the gastric mucosa. Active treatment and intervention before dysplasia can prevent the occurrence of cancer.

Among them, Chinese medicine, as an important category for the treatment of digestive tract and metabolic diseases, also plays a key role in various types of stomach diseases. In 2022, the article "Progress in Clinical and Mechanism Research on Traditional Chinese Medicine Treatment of Chronic Atrophic Gastritis" published in the "International Journal of Traditional Chinese Medicine and Materia Medica" stated that the main mechanisms of action of traditional Chinese medicine in the treatment of atrophic gastritis (CAG) include inhibiting malignant cell proliferation, inducing abnormal cell apoptosis, changing the microenvironment, reducing the degree of inflammation, repairing damaged mucosa, and improving immune function; in addition, the combination of traditional Chinese medicine and Western medicine not only enhances the efficacy, but also reduces adverse reactions, and has unique advantages in the treatment of CAG.
Renshu Jianwei Granules is a Class 1.1 new Chinese medicine applied by Zhongshan Pharmaceutical, mainly used for the treatment of atrophic gastritis and gastric mucosal precancerous lesions. It is reported that this variety is composed of eight Chinese medicinal materials such as Astragalus, Atractylodes, Coix Seed, Scutellaria, and Curcuma. It is an in-hospital preparation of Jiangsu Provincial Hospital of Traditional Chinese Medicine, which comes from decades of clinical experience of Professor Shan Zhaowei, the "First National Famous Chinese Medicine Practitioner".
Zhongshan Pharmaceutical mentioned in a press release that Qi deficiency, blood stasis, and heat depression are the pathological basis of CAG precancerous lesions, and "invigorating Qi, activating blood circulation, clearing heat and eliminating lumps" are the key to blocking and reversing CAG precancerous lesions. Renshu Jianwei Granules is a Chinese medicine based on the Qi-invigorating and stomach-nourishing method. It targets "Qi deficiency, blood stasis, and heat depression", one of the main pathogenesis of gastric mucosal precancerous lesions, and can be used to invigorate Qi, activate blood, and clear heat through syndrome differentiation and treatment to achieve the purpose of reversing gastric mucosal precancerous lesions. According to the official website of the China Clinical Trial Registry, the Phase III clinical study of Renshu Jianwei Granules for the treatment of chronic atrophic gastritis (Qi deficiency, blood stasis, and heat depression syndrome) has been completed.
The marketing application of Renshu Jianwei Granules was successfully accepted by CDE, which is expected to bring new options to relevant patients.

Recently, a number of innovative Chinese medicines have made new progress. According to the official website of CDE, the first-class 1.1 new Chinese medicines such as Yingke Rui's "Xiaoer Linglong Zaosheng Granules", Xinqikang Pharmaceutical's "Heat Relief and Cough Relief Granules", Tangning Pharmaceutical's "Xingnao Yizhi Capsules", and Kangyuan Pharmaceutical's "Guben Xiaozhan Granules" have all been submitted for clinical trials for the first time, or involve diseases in the fields of pediatrics, respiratory system, and nervous system...

With the country's increased support for the revival of Chinese medicine, China's Chinese medicine industry will continue to increase innovation and research and development, and more innovative results may be launched in the future. At the same time, the recognition of Chinese medicine in clinical and market is continuing to increase. According to Yaozhi data, there will be 8 large varieties of Chinese medicine with sales exceeding 2 billion in 2023, with total sales of 20.6 billion yuan.

As more and more innovative Chinese medicines obtain scientific evidence under a modern research and development system, the Chinese medicine industry will release more vigorous innovation vitality.

https://news.yaozh.com/archive/44713.html